solid-1029x579.png
Solid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021
May 11, 2021 08:00 ET | Solid Biosciences Inc.
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
solid-1029x579.png
Solid Biosciences Highlights Expertise in AAV Gene Therapy with Multiple Abstracts to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
May 04, 2021 08:00 ET | Solid Biosciences Inc.
-Data from studies of novel AAV vectors and AAV immunology and an encore of 12-month safety, efficacy and patient-reported outcomes measurements from the ongoing IGNITE DMD trial of SGT001 to be...
solid-1029x579.png
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
April 20, 2021 07:30 ET | Solid Biosciences Inc.
CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
solidbio_logo_1920x1080.png
Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
March 25, 2021 07:30 ET | Solid Biosciences Inc.
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
solidbio_logo_1920x1080.png
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
March 23, 2021 16:22 ET | Solid Biosciences Inc.
CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
SolidBioLogoDigitalRGB.png
Solid Biosciences Announces Pricing of Public Offering of Common Stock
March 18, 2021 21:14 ET | Solid Biosciences Inc.
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
SolidBioLogoDigitalRGB.png
Solid Biosciences Announces Proposed Public Offering of Common Stock
March 17, 2021 16:20 ET | Solid Biosciences Inc.
CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
SolidBioLogoDigitalRGB.png
Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort
March 15, 2021 16:15 ET | Solid Biosciences Inc.
- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function...
SolidBioLogoDigitalRGB.png
Solid Biosciences Reports Inducement Grant to New Chief Legal Officer
March 04, 2021 07:35 ET | Solid Biosciences Inc.
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
SolidBioLogoDigitalRGB.png
Solid Biosciences Announces Appointments to Management Team and Board of Directors
March 04, 2021 07:30 ET | Solid Biosciences Inc.
-Adding senior level experience to help advance programs for Duchenne muscular dystrophy- CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life...